The researchers conducted a population-based cohort study to investigate the association between SARS-CoV-2 vaccination and myocarditis or myopericarditis. Participants aged 12 years or older were diagnosed with myocarditis or myocarditis when the troponin levels increase and a hospital stay lasts more than 24 hours.
The study showed that an increased rate of myocarditis or myopericarditis was associated with mRNA-1273 (Moderna) vaccination compared with unvaccinated individuals, and was associated with BNT162b2 (Pfizer-BioNTech) among female participants. Nevertheless, this rate was low overall among female individuals and among younger age groups after SARS-CoV-2 mRNA vaccination, which provides evidence to support the overall safety of SARS-CoV-2 mRNA vaccines.
In addition, it is found out that there was an association between the significantly increased risk of cardiac arrest or death and SAR-CoV-2 infected individuals in the 28 days after a positive SAR-CoV-2 test compared with uninfected ones.